Your cart is empty.
Männedorf, Switzerland, June 7, 2013 - The Tecan Group (SIX Swiss Exchange: TECN) announced today that it has successfully completed the OEM development of the Dako Omnis. In May 2011, Tecan signed a major OEM agreement with Dako, an Agilent Technologies Company (NYSE: A) and worldwide provider of cancer diagnostics, for the development and supply of an advanced staining platform. Formerly the development program was referred to by Tecan as P16. The Dako Omnis instrument, co-developed with Dako and manufactured by Tecan, comprises hardware and software and sets new standards in automated tissue-based cancer diagnostics.
Tecan CEO David Martyr commented: "We are delighted that we successfully completed the development of the Dako Omnis as planned and only two years after signing the agreement. As communicated before, we expect sales volumes for Tecan from the supply of the Dako Omnis to accelerate from the second half of this year with a substantial contribution to our sales growth from 2014 onwards."
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2012, Tecan generated sales of CHF 391 million (USD 416 million; EUR 323 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89